Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
-
-
-
-
-
-
Allergen (AGN) PT Lowered to $212 at Deutsche Bank
-
-
-
-
-
-
-
Notable Analyst Rating Changes 10/31: (VMW) (M) (TEVA) Upgraded; (NKE) (ABBV) (JWN) Downgraded
-
-
-
-
-
-
-
Deutsche Bank Says Pfizer (PFE) and Allergan (AGN) Deal Would Enhance Cash Access
-
-
-
-
-
-
-
Deutsche Bank Maintains Buy Rating on Allergen (AGN)
-
-
-
-
-
-
-
Reduced Competition Adds $35 to Regeneron (REGN) DCF, Deutsche Bank Raises PT to $310
-
-
-
-
-
47,835 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All